Immunotherapy boosts hope for rectal cancer patients in new trial
NCT ID NCT04130854
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This study tests whether adding an immunotherapy drug called APX005M to standard treatment helps more people with advanced rectal cancer achieve a complete response, meaning no cancer cells remain after treatment. About 58 adults with stage II or III rectal cancer will be randomly assigned to receive standard therapy with or without the additional drug. The goal is to see if the combination leads to better outcomes without significantly increasing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390, United States
-
The University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
Wake Forest Baptist Health Sciences
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.